When it comes to buyouts among drugmakers, it’s hard to keep up with Valeant Pharmaceuticals’ (VRX) rapid pace of acquisitions. The Canadian drugmaker, which has already made a flurry of acquisitions this year, leads the 42-stock ethical drug makers group with a 99 Composite Rating. Other highly rated players in the group include Horizon (HZNP), Eli Lilly (LLY), Jazz Pharmaceuticals (JAZZ), Novo Nordisk (NVO) and AbbVie (ABBV).